RVW1 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume2.00K
Average Volume (3M)N/A
Market Cap
€2.54M
Enterprise Value€1.34M
Total Cash (Recent Filing)€257.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetHaving essentially zero reported debt provides durable financial flexibility and reduces near-term refinancing pressure. A clean leverage profile lets management prioritize operational progress and client wins without immediate debt service constraints, extending runway while pursuing growth.
Strong Revenue ReboundA material year-over-year revenue rebound signals recovering client demand and validates the fee-for-service model. If sustained, this trend supports scale economics and gives the company a clearer path to absorb fixed costs and improve margins over a multi-quarter horizon.
Specialized Oncology Modelling ServicesA focused, technical niche—computational oncology modelling—creates high switching costs and expertise-driven barriers to entry. Deep domain knowledge fosters long-term client relationships, repeat project pipeline and differentiated value in dose selection and translational decisions.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow indicates the business is not yet self-funding and will likely require external capital if losses continue. Persistent cash burn elevates refinancing and dilution risk and constrains capacity to invest in growth or R&D without fresh funding.
Ongoing Losses And Negative MarginsSustained net losses and weak margins show revenue growth has not yet translated into profitability. Continued negative results erode retained capital, limit reinvestment, and force management to choose between cost cuts, strategic pivots, or dilutive financings to bridge to profitability.
Small Equity Cushion And ROE StrainA limited equity buffer combined with sharply negative ROE signals vulnerability if losses persist. A small capital base raises the probability management must raise equity, which would dilute shareholders and could limit strategic flexibility during the multi-quarter recovery period.
Physiomics News
RVW1 FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is Physiomics PLC’s market cap?
Physiomics PLC’s market cap is €2.54M.
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 50 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Feb 16, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 453,208,700 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in DE:RVW1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Physiomics PLC
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.